Brief: SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
08/07/2024 13:58
July 8 (Reuters) - Sellas Life Sciences Group Inc
SLS.O :
* SELLAS RECEIVES EUROPEAN MEDICINES AGENCY ORPHAN DRUG
DESIGNATION FOR SLS009 FOR THE TREATMENT OF ACUTE MYELOID
LEUKEMIA
* SELLAS LIFE SCIENCES GROUP INC: ON TRACK TO SHARE FURTHER
DATA
AROUND SLS009 IN Q3 OF THIS YEAR
Source text for Eikon: ID:nGNX4PXgwz
Further company coverage: SLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses